CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma.
Sekino Y, Takemoto K, Murata D, Babasaki T, Kobatake K, Kitano H, Ikeda K, Goto K, Inoue S, Hayashi T, Taniyama D, Shigeta M, Kuraoka K, Mita K, Kaneko M, Sentani K, Oue N, Teishima J.
Sekino Y, et al. Among authors: teishima j.
Anticancer Res. 2021 Oct;41(10):4875-4883. doi: 10.21873/anticanres.15301.
Anticancer Res. 2021.
PMID: 34593435